Raltegravir News and Research

RSS
Most preferred drug for HIV may not be as safe as suggested

Most preferred drug for HIV may not be as safe as suggested

Researchers report first randomized trial results of 'kick and kill' approach to treat HIV

Researchers report first randomized trial results of 'kick and kill' approach to treat HIV

New HIV prevention guidelines from Canada released

New HIV prevention guidelines from Canada released

Nearly half of newly-infected HIV patients experience neurologic issues

Nearly half of newly-infected HIV patients experience neurologic issues

Subcutaneous injection of raltegravir can protect against vaginal HIV transmission

Subcutaneous injection of raltegravir can protect against vaginal HIV transmission

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Merck announces FDA approval of ISENTRESS for oral suspension

Merck announces FDA approval of ISENTRESS for oral suspension

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

FDA: New drug Tivicay approved to treat HIV-1 infection

FDA: New drug Tivicay approved to treat HIV-1 infection

Key HIV drug prices continue to fall, but newer medicines still priced too high

Key HIV drug prices continue to fall, but newer medicines still priced too high

Hidden HIV replication may be occurring within the body's tissue, researchers report

Hidden HIV replication may be occurring within the body's tissue, researchers report

Patients with drug-resistant HIV can safely achieve viral suppression without NRTIs

Patients with drug-resistant HIV can safely achieve viral suppression without NRTIs

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion